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Abstract
Background: The validation of novel diagnostic, prognostic and predictive biomarkers in cancer is crucial for optimizing
the choice and efficacy of personalized therapies. The aim of this study was to determine the epidermal growth factor
receptor (EGFR), epidermal growth factor receptor variant III (EGFRvIII) and amphiregulin (AREG) protein expression levels
and to evaluate the prognostic significance of EGFR, EGFRvIII and AREG in pancreatic ductal adenocarcinoma (PDAC).
Methods: The EGFR, EGFRvIII and AREG protein levels in PDAC (n = 92) were examined by using immunohistochemistry.
The associations between EGFRvIII expression, AREG expression, AREG/EGFR co-expression and clinicopathological
factors were assessed, the correlation between AREG and EGFR expression was analyzed and the survival analyses
were performed.
Results: Among the lesions of PDAC, 12 (13 %) stained positive for EGFRvIII, 49 (53.3 %) stained positive for AREG and
22(23.9 %) stained double positive for AREG/EGFR. The relationships between each protein expression level and the
clinicopathologic factors were examined, only AREG/EGFR co-expression was significantly related to tumor differentiation
(P = 0.032). The correlation between AREG and EGFR expression was statistically insignificant (P = 0.709). Univariate survival
analysis proved that high tumor-node-metastasis (TNM) stage, poor tumor differentiation and AREG expression were
significant poor prognostic factors for disease-free survival (DFS) and overall survival (OS). By multivariate survival analysis,
tumor differentiation was an independent poor prognostic factor for DFS (HR = 1.785, P < 0.05), whereas high TNM stage
(HR = 2.25, P < 0.05), poor tumor differentiation (HR = 2.125, P < 0.01), positive resection margins (HR = 1.84, P < 0.05), and
AREG expression (HR = 1.822, P < 0.05) were all independent poor prognostic factors for OS.
Conclusions: In conclusion, our data indicate that AREG expression is an important prognostic biomarker in PDAC .
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Background
Pancreatic ductal adenocarcinoma (PDAC) is the fourth
leading cause of cancer-related deaths in the United States
and the sixth leading cause of cancer-related deaths for
males in China with a 5-year survival rate of less than 7 %
[1, 2]. The majority of PDAC patients are diagnosed at an
advanced stage and thus are not candidates for treatment
with curative intent. Because PDAC patients usually show
partial responses to traditional cytotoxic chemotherapy,
specific molecule inhibition represents an attractive target
for cancer therapy. The epidermal growth factor receptor
(EGFR) has been increasingly recognized as a molecular
target in cancer therapy. The combination of gemcitabine
and erlotinib was the first combination therapy to demon-
strate survival benefits in advanced or metastatic pancre-
atic cancer in a phase III, double-blind, placebo-controlled
study [3]. As a result, gemcitabine-erlotinib combination
therapy was approved by the Food and Drug Adminis-
tration (FDA) for the first-line treatment of patients
with locally advanced non-resectable or metastatic pan-
creatic cancer.
Dysregulated EGFR signaling (such as cell-surface
overexpression, autocrine activation and EGFR gene mu-
tation) contributes to the formation of several epithelial
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malignancies in humans [4]. There is increasing recogni-
tion that epidermal growth factor receptor variant III
(EGFRvIII), the most common form of mutant EGFR, is
an important target for cancer therapy. EGFRvIII com-
prises an in-frame deletion of 267 amino acids from the
extracellular domain of EGFR. Although it is unable to
bind ligand, EGFRvIII shows a low-level constitutive kin-
ase activity and impaired endocytosis and degradation [5].
EGFRvIII is not detected in normal tissues, while it is over-
expressed in several cancer types, particularly glioblastoma
multiforme (GBM) [6]. However, whether EGFRvIII is
expressed in pancreatic cancer remains unclear.
Amphiregulin (AREG) is a member of ligand family
of EGFR. After bind to the extracellular ligand-binding
domain of EGFR, AREG activates intracellular signaling
cascades governing cell survival, proliferation, and mo-
tility [7]. Accordingly, several studies have focused on
the disruption of AREG-mediated oncogenic pathways.
AREG is upregulated in various neoplasms including
colon, lung, liver, breast, prostate, and pancreatic can-
cer [7]. Functional studies show that AREG is involved
in most of the hallmarks of cancer [8–11]. It has also
been reported that AREG expression is a promising
predictive marker for liver metastasis in primary colo-
rectal cancer [9]. Tinhofer et al. demonstrated that pa-
tients with squamous cell carcinoma of the head and
neck (SCCHN) who showed high AREG expression
were less likely to benefit from combination treatment
with cetuximab and docetaxel [10]. However, reports
regarding AREG expression in pancreatic cancer by
Park showed that decreased expression of AREG was a
typical characteristic of the tumor biology [11].
Therefore, the aims of our study were to investigate
the expression of EGFRvIII, AREG and AREG/EGFR co-
expression in resected PDAC tissues and to explore the




Patients who had preoperative chemotherapy (CT) or
radiotherapy (RT), macroscopic incomplete resection
(R2), or inadequate follow-up data and a survival time
of less than 30 days from the time of surgery were ex-
cluded in our study. The study population comprised
92 patients who underwent the resection for PDAC at
Peking Union Medical College Hospital during the
period between January 2009 and December 2014. The
study protocol was approved by the Institutional Ethics
Committee at Peking Union Medical College Hospital.
Written informed consent was obtained from all pa-
tients at the time of their treatment for use of material
in future research.
Clinicopathologic data
The medical records of enrolled patients were reviewed
from the pathologists’ electronic medical records system
at Peking Union Medical College Hospital. They included
the following data: age, sex, date of surgery, tumor loca-
tion, tumor size, pathologic stage (tumor-node-metastasis,
TNM stage), tumor differentiation, patterns and the site
of recurrence, patterns of resection margins. Disease free
survival (DFS) was determined from the time from sur-
gery until local or metastatic PDAC tumor recurrence.
Overall survival (OS) was defined as the time of surgery to
death. The follow-up period after the initial operation for
primary lesions was between 1 to 5 years.
Immunohistochemistry
For the immunohistochemical study, 92 formalin-fixed,
paraffin-embedded tumor specimens were collected. Con-
ventional 4-μm sections from the tissue blocks were used.
Immunohistochemistry was produced as previously de-
scribed [12]. The slides were incubated with a monoclonal
mouse anti-EGFR antibody (1:200 dilution; Santa Cruz), a
monoclonal mouse anti-EGFRvIII antibody (1:200 dilution;
Biorbyt), or a polyclonal goat anti-AREG antibody (1:50
dilution; R&D).
Evaluation of immunostaining
For the membranous and/or cytoplasmic expression levels
of EGFR and EGFRvIII, immunoreactivity was defined in
the same manner as previously described [13]. The cyto-
plasmic expression levels of AREG was socred by applying
a semi-quantitative immunoreactive score (IRS) system
[14]. Briefly, immunostatining intensity was scored as: 0 =
no staining, 1 = weak staining, 2 =moderate staining and 3
= strong staining. The extent of stained cells was stratified
into three groups based on the percentage of positive cells:
0 = 0 %, 1 = 1–33 %, 2 = 33–66 %; and 3= > 66 %. IRS scores
were obtained by multiplying the staining intensity by the
number of group which ranging from 0 to 9. The final IRS
scores >3 were considered AREG positive. The slides were
independently evaluated by two of the authors (LW and
HWW) to assess the protein expression levels.
Statistical analysis
The categorical variables were compared using the χ2 test.
The correlation between AREG and EGFR expression was
examined by Pearson’s test. Kaplan-Meier survival curves
were used to estimate the disease-free survival (DFS) and
overall survival (OS) of the patients which was determined
using the log-rank test. Multivariate analysis was per-
formed by Cox proportional hazard regression mode.
Two-sided P values < 0.05 were considered significant. All
statistical procedures were performed with SPSS software
for Windows, version 17.0 (SPSS Inc., Chicago, IL, USA).
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Results
Patient characteristics and Immunohistochemical analysis
Among the 92 PDAC patients, there were 50 men and 42
women with a median age of 61 years (range: 34-80 years).
The patient characteristics were described in Table 1.
In total, EGFRvIII expression of PDACs was 12 (13 %),
AREG expression of PDACs was 49 (53.3 %) and AREG/
EGFR co-expression of PDACs was22 (23.9 %). EGFR and
EGFRvIII was predominantly localized at the cellular
membrane, AREG were mainly detected in the cytoplasm.
Representative PDAC tissues with EGFR, EGFRvIII and
AREG expression profiles are shown in Fig. 1. The acinar
and ductal cells of the peritumoral areas showed negative
or weak staining for EGFR and AREG, whereas these pro-
teins were weakly or moderately expressed in normal pan-
creatic islet cells. Weak or moderate staining for AREG
was also observed in a majority of the fibroblasts.
A significant association between AREG/EGFR co-
expression and tumor differentiation was observed in our
study (P = 0.032). However, there was no significant associ-
ation between EGFRvIII expression or AREG expression
alone and clinicopathological characteristics in PDAC,
(Table 2).
Correlation between AREG and EGFR expression
Among 92 PDAC patients, 22 were positive for AREG and
EGFR expression, 21 were single-positive for EGFR, 27
were single-positive for AREG, and 22 were negative for
AREG and EGFR. The correlation between EGFR and
Table 1 Summary of baseline patient characteristics (n = 92)
Characteristic Variable Value
Age range (years) 34–80
Median 61
Mean 60
Sex Male vs. Female 50:42 (54.3 vs. 45.7 %)
Tumor location Head vs. Body/tail 52:40 (56.5 vs. 43.5 %)
Tumor size T1-2 vs. T3-4 23:69 (25 vs. 75 %)
TNM stage I-II vs. III-IV 80:12 (87 vs. 13 %)
Tumor differentiation Well/moderate vs. Poor 63:29 (68.5 vs. 31.5 %)
Lymph node metastasis Yes vs. No 51:41 (55.4 vs. 44.6 %)
Resection margins Positive vs. Negative 18:74 (20 vs. 80 %)
Fig. 1 Detection of EGFR, EGFRvIII, AREG expression in PDAC. a representative tumor samples with EGFR expression, ×100. b EGFR expression,
×200. c EGFRvIII expression, ×100. d EGFRvIII expression, ×200. e AREG expression, ×100. f AREG expression, ×200
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AREG expression was statistically insignificant (Φ = 0.039,
P = 0.709).
Prognostic Factors Affecting DFS and OS
The median follow-up for DFS and OS was 9.50 months
(range, 1–36 months) and 17.50 months (range, 2–48
months), respectively. The mean DFS and OS was
11.47 months and 17.71 months, respectively.
In the univariate survival analysis, high TNM stage
(P = 0.003 and P = 0.001), poor tumor differentiation
(P = 0.009 and P = 0.002) and AREG expression (P = 0.021
and P = 0.003) were significant adverse prognostic factors
for DFS and OS, respectively (Table 3, Fig. 2). PDAC pa-
tients with positive expression for AREG showed signifi-
cantly shorter DFS and OS (AREG-positive, 8 months vs.
AREG-negative, 12 months; AREG-positive, 16 months vs.
AREG-negative, 23 months). To analyze the prognostic
significance of the AREG/EGFR interaction, the study
population was divided into three groups: an AREG/EGFR
co-expression group, a single-positive group and a dual-
negative group. Using the log-rank test, however, none of
these groups showed significant differences in DFS or OS
(data not shown).
The hazard ratio (HR) was estimated by Cox regres-
sion, AREG expression was found to increase the HR for
recurrence (HR = 1.688, 1.059–2.691) and death (HR =
2.043, 1.238–3.374) (Table 3). Multivariate analysis was
performed to find independent factors that could affect
DFS and OS. Factors at the 0.10 level in the univariate
analysis (TNM stage, tumor differentiation, tumor size,
Resection margins, lymph node metastasis, AREG ex-
pression and AREG/EGFR co-expression) were entered
into a multivariate survival analysis. Poor tumor differ-
entiation was an independent unfavorable prognostic
factor for DFS (HR = 1.785, P = 0.021) and OS (HR =
2.125, P = 0.004). Moreover, AREG expression (HR =
1.822, P = 0.03), high TNM stage (HR = 225, P = 0.03),
and positive resection margins (HR = 1.84, P = 0.045)
Table 2 Correlation between EGFRvIII expression, AREG expression, AREG/EGFR co-expression and clinicopathologic factors in PDAC
Parameter EGFRvIII P AREG P AREG/EGFR P
Negative Positive Negative Positive Negativea Positiveb
Overall 80 12 43 49 70 22
Age(years) 0.056 0.241 0.65
< 60 30 8 15 23 28 10
≥ 60 50 4 28 26 42 12
Gender 0.124 0.566 0.057
Male 39 3 22 28 34 16
Female 41 9 21 21 35 6
Tumor sites 0.625 0.256 0.09
Head 46 6 27 25 43 9
Body/tail 34 6 16 24 27 13
Tumor size 0.475 0.117 0.158
T1-2 21 2 14 9 20 3
T3-4 59 10 29 40 50 19
TNM stage 0.187 0.106 0.925
I-II 71 9 40 40 61 19
III-IV 9 3 3 9 12 3
Tumor differentiation 0.885 0.803 0.032
Well/morderate 55 8 30 33 52 11
Poor 25 4 13 16 18 11
Resection margins 0.067 0.457 0.851
Negative 62 12 36 38 56 18
Positive 18 0 7 11 14 4
Lymph node metastasis 0.828 0.725 0.923
No 36 5 20 21 31 10
Yes 44 7 23 28 39 12
aNegative: single positive or dual-negative for AREG and EGFR
bPositive: AREG/EGFR coexpression(double positive for AREG and EGFR)
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were all independent prognostic indicators for poor OS
(Table 4).
Discussion
Unfortunately, PDAC is associated with a largely unfavor-
able outcome and aggressive tumor biology. Tumor size,
lymph node involvement and the status of the resection
margin are traditional prognostic factors, although they
are not adequate to distinguish between patients with a
high and low risk of disease recurrence and metastasis.
Our study is the first to simultaneously investigate the
clinicopathological and prognostic significance of EGFR-
vIII (the most common mutated variant of EGFR) expres-
sion, AREG (EGFR ligand) expression and AREG/EGFR
co-expression in PDAC. In our study, we showed that
AREG/EGFR co-expression were associated with poor
tumor differentiation. Also, AREG expression in PDAC
was an independent prognostic indicator of poor OS ac-
cording to our multivariate survival analysis.
According to previous immunohistochemical studies,
EGFR is expressed in 23.9–68.4 % of PDAC samples [12,
15]. Handra et al. [16] found that tumor expression of
EGFR was associated with clinical response but not out-
come in PDAC. Funatomi et al. demonstrated the existence
of an autoregulated AREG/EGFR feedback loop in pancre-
atic cancer [17]. After binding to EGFR, AREG stimulation
of the intrinsic tyrosine kinase activity of EGFR induces a
complex cascade of phosphorylation and activation events
that determine cell proliferation, differentiation, and tumor
development [18]. We found that the expression of AREG/
EGFR co-expression were associated with poor tumor dif-
ferentiation, which is consistent with previous studies.
In recent years, investigators have increasingly recog-
nized the critical role of EGFRvIII in tumor carcinogenesis
[19–21]. To the best of our knowledge, no published study
has correlated the expression of EGFRvIII with prognosis
in patients with pancreatic cancer. Evaluation of the ex-
pression of EGFRvIII in PDAC could provide additional
knowledge concerning the complex mechanism of EGFR
signaling in PDAC. EGFRvIII expression occurs at an
overall frequency of 25–64 % when assessed by multiple
techniques in GBM [20, 21]. Using immunohistochemis-
try, our study showed that 13 % (12 of 92) of PDAC
patients were positive for EGFRvIII. Tinhofer et al. [10]
found that expression of EGFRvIII was detected in 17 % of
SCCHN patients, expression of EGFRvIII was significantly
associated with shortened PFS but not with OS. In GBM,
EGFRvIII expression was associated with poor prognosis
Table 3 Univariate analysis for disease-free survival and overall survival
Parameter DFS OS
HR 95 % CI P HR 95 % CI P
Age(years) 0.944 0.84
≥ 60 (vs. < 60) 0.985 0.632–1.537 0.954 0.594–1.534
Gender 0.456 0.416
Female (vs. Male) 1.176 0.754–1.835 1.21 0.754–1.943
Tumor sites 0.69 0.629
Body/tail (vs. Head) 0.918 0.589–1.431 0.893 0.555–1.439
Tumor size 0.181 0.052
T3-4 (vs. T1-2) 1.379 0.836–2.274 1.658 0.967–2.843
TNM stage 0.003 0.001
III-IV (vs. I-II) 2.399 1.284–4.482 2.849 1.428–5.683
Tumor differentiation 0.009 0.002
Poor (vs. Well/moderate) 1.784 1.118–2.846 2.059 1.269–3.34
Resection margins 0.282 0.089
Positive (vs. Negative) 1.338 0.77–2.326 1.601 0.912–2.81
Lymph node metastasis 0.314 0.06
Yes (vs. No) 1.238 0.797–1.923 1.535 0.961–2.453
AREG expression 0.021 0.003
Positive (vs. Negative) 1.688 1.059–2.691 2.043 1.238–3.374
EGFRvIII expression 0.466 0.466
Positive (vs. Negative) 1.256 0.663–2.381 1.292 0.637–2.623
AREG/EGFR coexpression 0.08 0.166
Negative (vs. Positive) 0.853 0.646–1.128 0.831 0.619–1.115
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[20, 21]. However, our study suggests that EGFRvIII
expression has little prognostic significance on survival in
PDAC patients. Thus, the prognostic significance of
EGFRvIII expression in PDAC remains unclear and re-
quires further clarification.
AREG has been recognized as an oncogenic factor for
more than 20 years. The role of AREG in cancer devel-
opment and progression is supported by clinical data
showing that AREG can serve as a prognostic and/or a
predictive biomarker [22–26]. Masago et al. [24] found
that high serum levels of AREG and TGF-α were predic-
tors of poor prognosis in patients with advanced non-
squamous, non-small cell lung cancer (NSCLC). Simi-
larly, AREG expression was shown to be independently
associated with a reduced OS in a multivariate analysis
of 195 patients with stages I-III NSCLC [25]. Moreover,
the concomitant expression of AREG and EGFR was
associated with enhanced tumor aggressiveness and
shorter survival periods following tumor resection in
PDAC [26]. The results from in vitro and in vivo studies
have demonstrated that aberrantly activated AREG-
EGFR signaling is required for CRTC1-MAML2-positive
MEC (mucoepidermoid carcinoma) cell growth and sur-
vival. In particular, CRTC1-MAML2-positive MEC cells
are highly sensitive to EGFR signaling inhibition, which
suggests that EGFR-targeted therapies may benefit pa-
tients with MEC [27]. Consistent with these results, our
study demonstrated that high AREG expression was an
independent prognosticator of poor OS in PDAC. We
also found that AREG/EGFR co-expression was associated
with poor tumor differentiation, which is similar to that
demonstrated in previous studies [22–26]. Recently, one
study with conflicting results reported that the negative
expression of AREG and positive expression of MMP-2
were hallmarks of tumor biology in PDAC patients [11].
Park et al. enrolled 88 PDAC patients and stained EGFR,
AREG, VEGF, p-c-met, MMP2, MMP7, MMP9, CXCR3,
and CXCR4 antibodies on tissue microarray (TMA) [11].
On the contrary, we stained our markers on whole tissue
sections, which provided a wider scope and improved per-
ception of tumor heterogeneity, eliminating potential bias.
Compared with their uniform interpretation criteria, we
adopted different criteria for positivity membranous stain-
ing and cytoplasmic staining. However, both studies were
subjected to several limitations including limited sample
size and lack the in-depth investigation into the pro-
oncogenic mechanism of AREG in PDAC.
Numerous researchers have reported that AREG was cor-
related with invasion and distant metastases in multiple
malignancies [28–30]. Increasing evidences revealed that
the essential role of EMT in the local invasion and metasta-
sis of pancreatic cancer. To study the role of AREG in the
EMT of PDAC may provide insights into the tumor biology
of PDAC cell migration and invasion for inspiration.
Fig. 2 Predictors of DFS and OS in PDAC. Kaplan-Meier curves for DFS (top) and OS (bottom) of PDAC patients with TNM stage (a), Tumor differ-
entiation (b) and AREG expression (c). P values for comparison of groups using the log-rank test are given
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Conclusions
Our results showed that although no significant association
was observed between AREG expression alone and the
clinicopathological characteristics in PDAC, there was a sig-
nificant association between AREG/EGFR co-expression
and poor tumor differentiation. Moreover, AREG expres-
sion, poor tumor differentiation, high TNM stage, and posi-
tive resection margins were all independent prognostic
indicators for poor OS. Our data indicate that AREG
expression identifies a subset of PDAC patients with more
aggressive tumor characteristics and a significantly worse
prognosis, indicating that AREG may serve as an attractive
therapeutic strategy for PDAC.
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Additional file 1: Figure S1. AREG RNA and protein levels in pancreatic
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cancer cells and pancreatic stellate cells. B, AREG protein levels in pancreatic
cancer cells and pancreatic stellate cells, * indicates a P < 0.05. (DOC 718 kb)
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